Howard A. Burris
The Sarah Cannon Research Institute
250 25th Avenue North
Suite 110
Nashville
USA
Name/email consistency: high
- A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Burris, H.A., Jones, S.F., Williams, D.D., Kathman, S.J., Hodge, J.P., Pandite, L., Ho, P.T., Boerner, S.A., Lorusso, P. Invest. New. Drugs (2011)
- New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Burris, H., Rocha-Lima, C. Oncologist (2008)
- Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?. Burris, H.A. Semin. Oncol. (2006)
- Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Burris, H.A., Rivkin, S., Reynolds, R., Harris, J., Wax, A., Gerstein, H., Mettinger, K.L., Staddon, A. Oncologist (2005)
- Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris, H.A., Hurwitz, H.I., Dees, E.C., Dowlati, A., Blackwell, K.L., O'Neil, B., Marcom, P.K., Ellis, M.J., Overmoyer, B., Jones, S.F., Harris, J.L., Smith, D.A., Koch, K.M., Stead, A., Mangum, S., Spector, N.L. J. Clin. Oncol. (2005)
- Recent updates on the role of chemotherapy in pancreatic cancer. Burris, H.A. Semin. Oncol. (2005)
- Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. Burris, H., Yardley, D., Jones, S., Houston, G., Broome, C., Thompson, D., Greco, F.A., White, M., Hainsworth, J. J. Clin. Oncol. (2004)
- Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Burris, H.A. Oncologist (2004)
